The human immune response during cutaneous leishmaniasis: NO problem

Parasitology Today

Volumn 15, Issue 8, 1999, Pages 342-345

  Mossalayi, M Djavad ^a   Arock, Michel ^a   Mazier, Dominique ^b   Vincendeau, Phillipe ^c   Vouldoukis, Ioannis ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MEMBRANE ANTIGEN; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN; IMMUNE RESPONSE; LEISHMANIA; MACROPHAGE; MOUSE; NONHUMAN; SKIN LEISHMANIASIS; T LYMPHOCYTE;

VERMES;

EID: 0033178579     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(99)01477-5     Document Type: Review

References (29)

1. Liew F.Y.et al. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144:1990;4793-4802.
2. Green S.J.et al. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. 144:1990;278-286.
3. Stenger S.et al. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J. Exp. Med. 180:1994;783-793.
4. Reed S.G., Scott P. T-cell and cytokine responses in leishmaniasis. Curr. Biol. 5:1993;524-531.
5. Vouldoukis I.et al. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the FcεRII/CD23 surface antigen. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7804-7808.
6. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:1995;151-177.
7. Modlin R.L., Nutman T.B. Type 2 cytokines and negative regulation in human infections. Curr. Opin. Immunol. 5:1993;511-517.
8. Bogdan C.et al. Invasion, control and persistence of Leishmania parasites. Curr. Opin. Immunol. 8:1996;517-525.
9. Skeiky Y.A.W.et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Thl-type cytokine profile and to produce interleukin-12. J. Exp. Med. 181:1995;1527-1537.
10. Mougneau E.et al. Expression and cloning of a protective Leishmania antigen. Science. 268:1995;563-566.
11. Campos-Neto A.et al. Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J. Exp. Med. 182:1995;1423-1433.
12. + cytotoxic T cells and Leishmania-infected macrophages. J. Exp. Med. 174:1991;499-505.
13. Murray H.W., Rubin B.Y., Rethermel C.D. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon γ is the activating lymphokine. J. Clin. Invest. 72:1983;1506-1510.
14. Barral-Netto M.et al. Tumor necrosis factor/cachectin in human visceral leishmaniasis. J. Infect. Dis. 163:1991;853-857.
15. Denis M. Human monocytes/macrophages: NO or no NO? J. Leukocyte Biol. 55:1994;682-684.
16. Scott P.et al. Early IL-4 production does not predict susceptibility to Leishmania major. Exp. Parasitol. 84:1996;178-187.
17. Vouldoukis I.et al. CD23 and IgE expression during human immune response to cutaneous leishmaniasis: possible role in monocyte activation. Res. Immunol. 145:1994;17-27.
18. Coutinho S.G.et al. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp. Parasitol. 84:1996;144-155.
19. Mossalayi M.D., Arock M., Debré P. CD23/FcεRII: signaling and clinical implication. Int. Rev. Immunol. 16:1997;129-146.
20. Dugas B.et al. Nitric oxide production by human monocytes: evidence for a role of CD23. Immunol. Today. 16:1995;574-580.
21. Vouldoukis I.et al. Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur. J. Immunol. 27:1997;860-865.
22. Primez C.et al. Cytokine patterns in the pathogenesis of human leishmaniasis. J. Clin. Invest. 91:1993;1390-1395.
23. Melby P.C.et al. In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. FEMS Immunol. Med. Microbiol. 15:1996;101-107.
24. Barral A.et al. Transforming growth factor-β as a virulence mechanism for Leishmania braziliensis. Proc. Natl. Acad. Sci. U. S. A. 90:1993;3442-3446.
25. Nussler A., Billiar T.R. Inflammation, immunoregulation, and inducible nitric oxide synthase. J. Leukocyte Biol. 54:1993;171-178.
26. Moncada S., Higgs E.A. The L-arginine-nitric oxide pathway. New Engl. J. Med. 329:1993;2002-2012.
27. De Maria R.et al. Triggering of human monocyte activation through CD69, a member of the natural killer gene complex family of signal transducing receptors. J. Exp. Med. 180:1994;1999-2004.
28. Assreuy J.et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur. J. Immunol. 24:1994;672-676.
29. Lopez-Jaramillo P.et al. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet. 351:1998;1176-1177.